AZN buys optionality on a potential Keytruda-rival mechanism for just 0.8% of its market cap, retaining full rights to its own ADC pipeline while avoiding outright acquisition risk.

The IPKat blog reports on copyright, patent, trade mark, info-tech and confidentiality issues from a mainly UK and European perspective.

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

Novo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharma

$SMMT: AstraZeneca’s agreed $2B investment, dilution, GI combination study and the separate ESMO and FDA milestones.

AstraZeneca invests $2B in Summit for a ~12% stake plus a combo trial pairing ivonescimab with its Claudin 18.2 ADC.

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

According to Bank of England data, August mortgage approvals hit their lowest level since December 2023 due to rising borrowing costs. UK diesel prices reached record highs amid crude oil increases, burdening consumers and businesses. In pharmaceuticals, Novo Nordisk and AstraZeneca are pursuing major acquisitions and partnerships. Meanwhile, AI development faces setbacks due to safety concerns and test failures.

AstraZeneca committed $2 billion to Summit Therapeutics on the same day strong lung cancer survival data landed, closing the short case on capital risk.

Summit and AstraZeneca will co-develop ivonescimab combinations, starting with GI cancers. Each company keeps rights to its own medicines.